Comparative gender analysis of the efficacy and safety of atazanavir/ritonavir and lopinavir/ritonavir at 96 weeks in the CASTLE study

Journal of Antimicrobial Chemotherapy

Volumn 66, Issue 2, 2011, Pages 363-370

  Squires, Kathleen E ^a   Johnson, Margaret ^b   Yang, Rong ^c   Uy, Jonathan ^c   Sheppard, Louise ^c   Absalon, Judith ^c   McGrath, Donnie ^c  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b ROYAL FREE HOSPITAL   (United Kingdom)

^c BRISTOL MYERS SQUIBB   (United States)

Author keywords

Antiretroviral therapy; HIV; Protease inhibitors

Indexed keywords

ATAZANAVIR PLUS RITONAVIR; CHOLESTEROL; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOPINAVIR PLUS RITONAVIR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; VIRUS RNA;

ADULT; AGED; ARTICLE; CD4 LYMPHOCYTE COUNT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HYPERBILIRUBINEMIA; JAUNDICE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); NAUSEA; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCLERA DISEASE; SCLERAL ICTERUS; SEX DIFFERENCE; SIDE EFFECT; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL; VOMITING;

ADULT; AGED; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; DRUG THERAPY, COMBINATION; DRUG TOXICITY; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; OLIGOPEPTIDES; PYRIDINES; PYRIMIDINONES; RITONAVIR; SEX FACTORS;

EID: 78651467285     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkq457     Document Type: Article

References (34)

1. UNAIDS. 2008 Report on the Global HIV/AIDS Epidemic. http://www.unaids.org/en/knowledgecentre/hivdata/globalreport/2008/2008_global_report.asp (24 April 2010, date last accessed).
2. UNAIDS/WHO. AIDS Epidemic Update, 2009. http://data.unaids.org/pub/Report/2009/JC1700_Epi_Update_2009_en.pdf (24 April 2010, date last accessed).
3. Belden KA, Squires KE. HIV infection in women: do sex and gender matter? Curr Infect Dis Rep 2008; 10: 423-31.
4. Pardo M, Ruiz M, Gimeno A. Gender bias in clinical trials of AIDS drugs. In: Abstracts of the Fourteenth International AIDS Conference, Barcelona, Spain, 2002. Abstract WePeB5964. http://gateway.nlm.nih.gov/gw/Cmd?GMResultsSummary%261oc=nccs (25 October 2010, date last accessed).
5. Currier J, Averitt BD, Hagins D et al. Sex-based outcomes of darunavirritonavir therapy: a single-group trial. Ann Intern Med 2010; 153: 349-57.
6. Fourie J, Flamm J, Rodriguez-French A. ARTEMIS: week 96 safety and efficacy of darunavir/r by gender, age and race. In: Abstracts of the Fifth IAS Conference on HIV Pathogenesis, Treatment and Prevention, Cape Town, South Africa, 2009. Abstract CDB072. http://library.iasociety.org/AbstractView.aspx?confID=2009&abstractId=1831 (25 October 2010, date last accessed).
7. Walmsley SL, Squires K, Weiss L et al. Multidrug-experienced HIV-1-infected women demonstrated similar virological and immunological responses to tipranavir/ritonavir compared with men. AIDS 2009; 23: 429-31.
8. Absalon J, Uy J, Yang R et al. Gender-based differences in ARV-naive patients treated with boosted protease inhibitors: results from the CASTLE study (AI424138). In: Abstracts of the Seventeenth International AIDS Conference, Mexico City, 2008. Abstract TUPE0062. http://www.aids2008-abstracts.org/aids2008_book_vol1_web.pdf (25 October 2010, date last accessed).
9. Moore AL, Kirk O, Johnson AM et al. Virologic, immunologic, and clinical response to highly active antiretroviral therapy: the gender issue revisited. J Acquir Immune Defic Syndr 2003; 32: 452-61.
10. Murphy RL, Gulick RM, DeGruttola V et al. Treatment with amprenavir alone or amprenavir with zidovudine and lamivudine in adults with human immunodeficiency virus infection. AIDS Clinical Trials Group 347 Study Team. J Infect Dis 1999; 179: 808-16.
11. Tedaldi EM, Absalon J, Thomas AJ et al. Ethnicity, race, and gender. Differences in serious adverse events among participants in an antiretroviral initiation trial: results of CPCRA 058 (FIRST Study). J Acquir Immune Defic Syndr 2008; 47: 441-8.
12. Kumar PN, Rodriguez-French A, Thompson MA et al. A prospective, 96-week study of the impact of Trizivir, Combivir/nelfinavir, and lamivudine/stavudine/nelfinavir on lipids, metabolic parameters and efficacy in antiretroviral-naive patients: effect of sex and ethnicity. HIV Med 2006; 7: 85-98.
13. Dieleman JP, Jambroes M, Gyssens IC et al. Determinants of recurrent toxicity-driven switches of highly active antiretroviral therapy. The ATHENA cohort. AIDS 2002; 16: 737-45.
14. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents, December 1, 2009. http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf (10 December 2009, date last accessed).
15. Jacobs RJ, Kane MN. HIV-related stigma in midlife and older women. Soc Work Health Care 2010; 49: 68-89.
16. Molina JM, Andrade-Villanueva J, Echevarria J et al. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study. Lancet 2008; 372: 646-55.
17. Molina JM, Andrade-Villaneuva J, Echevarria J et al. Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study. J Acquir Immune Defic Syndr 2010; 53: 323-32.
18. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143-421.
19. Malan DR, Krantz E, David N et al. Efficacy and safety of atazanavir, with or without ritonavir, as part of once-daily highly active antiretroviral therapy regimens in antiretroviral-naive patients. J Acquir Immune Defic Syndr 2008; 47: 161-7.
20. Elion R, Cohen C, Ward D et al. Evaluation of efficacy, safety, pharmacokinetics, and adherence in HIV-1-infected, antiretroviral-naive patients treated with ritonavir-boosted atazanavir plus fixed-dose tenofovir DF/emtricitabine given once daily. HIV Clin Trials 2008; 9: 213-24.
21. Eron J Jr, Yeni P, Gathe J Jr et al. The KLEAN study of fosamprenavirritonavir versus lopinavir-ritonavir, each in combination with abacavirlamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial. Lancet 2006; 368: 476-82.
22. Ortiz R, DeJesus E, Khanlou H et al. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48. AIDS 2008; 22: 1389-97.
23. Ananworanich J, Gayet-Ageron A, Ruxrungtham K et al. Long-term efficacy and safety of first-line therapy with once-daily saquinavir/ritonavir. Antivir Ther 2008; 13: 375-80.
24. Gathe J, da Silva B, Loutfy M. Study M05-730 primary efficacy results at week 48: phase 3, randomized, open-label study of lopinavir/ritonavir tablets once daily vs twice daily, co-administered with tenofovir and emtricitabine in ARV-naive HIV-1-infected subjects. In: Abstracts of the Fifteenth Conference on Retrovirus and Opportunistic Infections, Boston, MA, 2008. Abstract 775. http://www.retroconference.org/2008/PDFs/775.pdf (25 October 2010, date last accessed).
25. da Silva BA, Cohen D, Gibbs S et al. Impact of gender on response to lopinavir/ritonavir (LPV/r) tablets dosed QD or BID administered with tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC) in antiretroviral-naïve (ARV) subjects: results from study M05-730. In: Abstracts of the Seventeenth International AIDS Conference, Mexico City, 2008. Abstract TUPE0069. http://www.aids2008-abstracts.org/aids2008_book_vol1_web.pdf (25 October 2010, date last accessed).
26. Hoffman RM, Umeh OC, Garris C et al. Evaluation of sex differences of fosamprenavir (with and without ritonavir) in HIV-infected men and women. HIV Clin Trials 2007; 8: 371-80.
27. Andrade-Villaneuva J, Herrera G, Chiliade P et al. ARTEMIS: week 48 safety and efficacy of darunavir/r by gender, age and race. In: Abstracts of the Seventeenth International AIDS Conference, Mexico City, 2008. Abstract TUPE0064. http://www.aids2008-abstracts.org/aids2008_book_vol1_web.pdf (25 October 2010, date last accessed).
28. Mocroft A, Gill MJ, Davidson W et al. Are there gender differences in starting protease inhibitors, HAART, and disease progression despite equal access to care? J Acquir Immune Defic Syndr 2000; 24: 475-82.
29. Roberts KJ, Mann T. Barriers to antiretroviral medication adherence in HIV-infected women. AIDS Care 2000; 12: 377-86.
30. Riddler SA, Haubrich R, DiRienzo AG et al. Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med 2008; 358: 2095-106.
31. Kaletra. [US prescribing information]. Chicago, IL: Abbott Laboratories; 2009.
32. Reyataz. [US prescribing information]. Princeton, NJ: Bristol-Myers Squibb; 2009.
33. Zhang J, Chung E, Yones C et al. The effect of atazanavir/ritonavir on the pharmacokinetics of an oral contraceptive containing ethinyl estradiol and norgestimate in healthy women. Antivir Ther in press.
34. Gordillo V, Fekete EM, Platteau T et al. Emotional support and gender in people living with HIV: effects on psychological well-being. J Behav Med 2009; 32: 523-31.